Developer docs
API playgroundTry for free, no card

Search company profiles

Sapphiros

Full company profile

uuid0000z3b

Namestring
Sapphiros
Legal namestring
Sapphiros LLC
Websiteurl
sapphiros.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Sapphiros is a privately held consumer diagnostics platform company founded in 2021 and headquartered in Boston, Massachusetts. The company is backed by KKR and Neoenta (with KKR board representation from Ali Satvat and Anuv Ratan) and operates through multiple wholly-owned subsidiaries including Biocrucible (isothermal molecular diagnostics), Satio (patch-based blood collection and drug delivery), GrapheneDx (graphene field effect transistor biosensors), Flexotronix (printed electronics manufacturing), GoToKnow (COVID-19 antigen rapid tests), and NowFuture (DTC wellness brand). It maintains engineering/R&D operations in Cambridge, UK and high-volume manufacturing in Hove, UK, with operating geographies spanning the USA, UK, and Senegal.

The company's core technology platform centers on four diagnostic technology lines: Handheld 1-step Molecular (instrument-free isothermal nucleic acid amplification via RPA technology invented by CTO Niall Armes), Digital Lateral Flow (connected lateral flow tests with electronic readout via exclusive Ynvisible e-paper display supply), Blood Collection & Detection (Satio Draw upper-arm patch replacing finger pricks), and traditional Lateral Flow. These are underpinned by vertically integrated capabilities including Extreme Volume Manufacturing (5 billion unit annual capacity, 16 million tests per day using 35 operators via reel-to-reel processes), Printed Electronics (integration of heaters, batteries, sensors, and antennae onto flexible materials), and In-house Molecular Reagents (peptides, oligonucleotides, recombinant proteins).

Sapphiros generates revenue through hardware sales of diagnostic products, manufacturing capacity access via strategic agreements (notably the Roche agreement providing access to 1 billion lateral flow tests annually), technology licensing, and DTC consumer wellness products via NowFuture.com and Amazon.com. Distribution occurs through multiple channels: enterprise sales to healthcare providers and government health agencies, pharmacy distribution via Cencora, exclusive distribution rights with OraSure Technologies, and DTC e-commerce. The company has accumulated over $14.6M in non-dilutive government grants from NIH RADx, ARPA-H, BARDA, and the Gates Foundation. Its customer base spans enterprise (Roche, OraSure, Cencora, Ynvisible, Visby), government (NIH, BARDA, ARPA-H, Gates Foundation), and global health (Institut Pasteur de Dakar).

Short descriptiontext

Sapphiros is a privately held consumer diagnostics platform company developing low-cost molecular, lateral flow, and patch-based diagnostic tests. Backed by KKR and Neoenta, it serves healthcare providers, government agencies, and consumers through its 5-billion-unit annual manufacturing capacity.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, lateral flow assays, blood collection devices, point-of-care testing, diagnostic manufacturing
Industry2 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code4 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical and Diagnostic Laboratories6215
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
SIC code4 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Testing Laboratories8734
  • Laboratory Analytical Instruments3826
Product category
Consumer Diagnostics
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Diagnostic Products
TypeHardware Sales
Description

Sale of consumer and professional diagnostic tests including lateral flow tests, molecular diagnostics, digital lateral flow devices, and blood collection/detection products. Revenue from product sales to healthcare providers, pharmacies, and consumers.

sapphiros.com
2Manufacturing Capacity Access
TypeTransaction Fee
Description

Strategic supply and manufacturing agreements providing partners like Roche access to manufacturing capacity for lateral flow tests and future molecular point-of-care tests.

sapphiros.com
3Technology Licensing
TypeLicensing Royalties
Description

Licensing of proprietary technologies and platforms to partners for development and commercialization of diagnostic products.

sapphiros.com
4Consumer Wellness Products
TypeOne Time License
Description

Direct-to-consumer genomic and wellness testing through NowFuture brand, sold via website, Amazon.com, and retail partners.

sapphiros.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1GoToKnow
Description

Brand for COVID-19 antigen rapid tests and related diagnostic products

sapphiros.com
+4 more records
Core offering1 text field

Sapphiros develops and manufactures low-cost, scalable consumer and clinical diagnostic platforms spanning molecular diagnostics, lateral flow, digital lateral flow, and at-home blood collection systems. The company operates a UK-based extreme volume manufacturing facility with annual capacity of 5 billion tests, combining proprietary printed electronics, in-house molecular reagents, and novel sample collection technologies. It sells through its NowFuture direct-to-consumer wellness brand and through strategic distribution partnerships with Cencora, OraSure, and Roche.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 5 billion tests annually manufacturing capacity
+4 more records
Product overview1 text field

Sapphiros is a privately held consumer diagnostics platform company offering a multi-product portfolio across four core diagnostic technology lines: Handheld 1-step Molecular (instrument-free isothermal nucleic acid testing for home and point-of-care), Digital Lateral Flow (connected lateral flow with electronic readout and NFC smartphone app connectivity), Blood Collection & Detection (Satio Draw and Satio Dot at-home blood collection patches replacing finger pricks), and Lateral Flow (extreme-scale rapid tests for global health). The company also operates a direct-to-consumer wellness sub-brand, NowFuture, offering genomic tests. Underpinning the product portfolio are four manufacturing and technology capabilities: Extreme Volume Manufacturing (EVM, producing up to 5 billion tests annually via reel-to-reel processes), Printed Electronics (reel-to-reel integration of batteries, heaters, sensors, and antennae), In-house Molecular Reagents (vertically integrated probe/protein/biochemistry production), and Visual Lateral Flow. Sapphiros also integrates Ynvisible e-paper displays into its next-generation diagnostic devices. The platform targets respiratory disease, infectious disease, and blood collection/detection focus areas.

Product and service6 records
1Handheld 1-step Molecular Platform
CategoryMolecular Diagnostics
Description

Instrument-free, connected molecular diagnostics platform bringing lab-quality nucleic acid testing to point-of-care and home settings via isothermal amplification in a single user step, with built-in connectivity and multiplex capabilities for multiple answers from a single test.

2Digital Lateral Flow
CategoryDigital Diagnostics
Description

Connected lateral flow testing platform with digital readout that eliminates ambiguous visual interpretation, delivering clear objective results on a large display with optional NFC-based app connectivity for tracking and healthcare system integration.

3Blood Collection & Detection (Satio)
CategorySample Collection Devices
Description

At-home blood collection systems comprising Satio Draw (upper-arm self-collection for lab analysis) and Satio Dot (dried blood spot collection), designed to replace finger pricks and clinic visits with comfortable simple home-based sampling.

4Lateral Flow Diagnostics (GoToKnow)
CategoryLateral Flow Diagnostics
Description

Rapid lateral flow diagnostic platform engineered for extreme manufacturing scale and ultra-low costs, with five billion unit annual production capacity, integrated packaging reducing material costs and environmental impact, including the GoToKnow brand of COVID-19 antigen rapid tests.

5NowFuture Wellness Brand
CategoryConsumer Genomics and Wellness
Description

Direct-to-consumer wellness brand offering genomic tests for nutrition, fitness, and sleep, with planned expansion into at-home blood collection and detection, women's health, and infectious disease testing.

6SatioRx Intradermal Drug Delivery System
CategoryDrug Delivery Devices
Description

Remotely controllable intradermal drug delivery device with disposable microneedle components designed for precise metered dose delivery of liquid drugs in compact, inexpensive form factor.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-11
Description

Letter of Intent for Sapphiros to become exclusive supplier of e-paper displays for Sapphiros' lateral flow and molecular diagnostic tests. Three-year exclusive supply agreement planned. Represents Ynvisible's first commercial entry into medical diagnostics market with commercial sales expected to accelerate throughout 2026 pending FDA approval.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-01
Description

Delivered more than 10,000 units of e-paper displays to Sapphiros supporting clinical trials and next-generation diagnostic devices.

3BARDA
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Collaboration for development of OTC single-use, low-cost digital antigen test that can detect and differentiate between respiratory viruses. The NowFuture Digital Flu/COVID Test incorporates digital readout and smartphone app connectivity.

sapphiros.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-11-19
Description

Strategic supply and manufacturing option agreement granting Roche exclusive rights to lateral flow technology manufacturing capacity of at least 1 billion tests annually. Includes access to Sapphiros' future instrument-free, multiplex molecular platform for point-of-care and home testing. Secures rapid global access to tests for future pandemics and health emergencies.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-04
Description

Strategic distribution agreement and investment. OraSure secured exclusive distribution rights for Sapphiros products in development. Partnership leverages OraSure's commercial infrastructure to scale diagnostics following regulatory approvals with initial distribution planned for 2024 and more launches expected in 2025.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-11-22
Description

Distribution agreement for GoToKnow COVID-19 Antigen Rapid Tests to pharmacies across the United States. Future access to Sapphiros technologies including multiplexed molecular diagnostics platform, additional rapid lateral flow tests, and Satio blood collection patches.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-06
Description

Strategic partnership to industrialize graphene-based biosensors for medical devices. GrapheneDx brings GFET biosensor technology, General Graphene supplies CVD graphene, and Sapphiros contributes extreme volume manufacturing and commercialization expertise.

8General Graphene Corporation
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-06-06
Description

Preferred supplier of sheet-based CVD graphene in roll-to-roll format for use in Sapphiros' extreme volume manufacturing facility. Annual capacity to supply 100,000 square meters of sheet graphene.

sapphiros.com
9Institut Pasteur de Dakar
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2022-08-23
Description

Strategic partnership for research, development, manufacture, and distribution of next generation healthcare technologies. Aims to enable low-cost access to vaccines and diagnostics to advance public health in Africa and beyond.

sapphiros.com
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2022-08-22
Description

Strategic partnership to jointly improve delivery of mass vaccination using SatioRx intradermal patches and INTACT aseptic fluid transfer technology. Focus on Yellow Fever, COVID (mRNA), and malaria vaccines for African Union Member States.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

OraSure is both a strategic investor/distribution partner and a competitor in consumer and point-of-care diagnostics (HIV self-testing, HCV, COVID). Its dual role mirrors Sapphiros' own position across consumer wellness, infectious disease, and OTC channels, making it a uniquely comparable peer.

TypeDirect peer
Description

Visby Medical develops single-use, instrument-free PCR diagnostic platforms for respiratory infections and sexual health. It is the closest direct competitor to Sapphiros' handheld 1-step molecular platform, sharing the same instrument-free point-of-care thesis; multiple Sapphiros executives (including Teresa Abraham, KC McGrath, and Ryan Schmidt) came from Visby, making it an unusually clean comparable.

TypeDirect peer
Description

23andMe is a consumer genomics company selling direct-to-consumer DNA tests for ancestry, health, and wellness. It is the dominant competitor to NowFuture's genomic test line for nutrition, fitness, and sleep, with comparable e-commerce and Amazon distribution.

4Cue Health
TypeDirect peer
Description

Cue Health is a consumer-focused molecular diagnostics company offering connected at-home COVID and respiratory tests. It overlaps directly with Sapphiros' NowFuture DTC strategy and handheld molecular platform, with similar go-to-market emphasis on direct consumer and pharmacy channels.

TypeDirect peer
Description

iHealth Labs scaled rapidly into consumer COVID and at-home diagnostic testing through Amazon and pharmacy distribution, directly mirroring Sapphiros' NowFuture DTC and Cencora pharmacy channel strategy. Both target the same OTC rapid-test buyer.

TypeDirect peer
Description

Everlywell is a leading direct-to-consumer diagnostic testing brand offering at-home collection for a broad menu of wellness and infectious disease tests. It is the closest consumer-brand analog to Sapphiros' NowFuture genomic and wellness offering.

TypeEmerging player
Description

Tasso develops at-home blood collection patches (OnDemand) that enable remote sample collection for laboratory analysis. It is the most direct emerging competitor to Sapphiros' Satio Draw and Satio Dot patch-based blood collection technology, sharing the same painless at-home sample collection value proposition.

TypeBroad incumbent
Description

QuidelOrtho is a major diagnostics incumbent with QuickVue and Sofia lateral flow franchises and a broader immunoassay portfolio. It competes directly with Sapphiros in respiratory rapid antigen testing and shares the same retail pharmacy and hospital channels.

TypeBroad incumbent
Description

BD's Diagnostic Systems segment includes the Veritor lateral flow platform and a broad rapid testing portfolio sold into US hospitals and pharmacies. It is an incumbent competitor with overlapping respiratory and infectious disease menu and similar scale economics ambitions.

10Abbott Diagnostics (BinaxNOW / Panbio)
TypeBroad incumbent
Description

Abbott is the dominant incumbent in lateral flow rapid antigen testing through BinaxNOW and Panbio, with deep retail pharmacy and global health distribution. It is the benchmark competitor for Sapphiros' lateral flow scale strategy and the legacy operator Sapphiros' founder previously ran (Alere, acquired by Abbott for $8B).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries7 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sapphiros

Consumer Diagnosticssapphiros.com

Sapphiros is a privately held consumer diagnostics platform company developing low-cost molecular, lateral flow, and patch-based diagnostic tests. Backed by KKR and Neoenta, it serves healthcare providers, government agencies, and consumers through its 5-billion-unit annual manufacturing capacity.

What Sapphiros does

Sapphiros is a privately held consumer diagnostics platform company founded in 2021 and headquartered in Boston, Massachusetts. The company is backed by KKR and Neoenta (with KKR board representation from Ali Satvat and Anuv Ratan) and operates through multiple wholly-owned subsidiaries including Biocrucible (isothermal molecular diagnostics), Satio (patch-based blood collection and drug delivery), GrapheneDx (graphene field effect transistor biosensors), Flexotronix (printed electronics manufacturing), GoToKnow (COVID-19 antigen rapid tests), and NowFuture (DTC wellness brand). It maintains engineering/R&D operations in Cambridge, UK and high-volume manufacturing in Hove, UK, with operating geographies spanning the USA, UK, and Senegal.

The company's core technology platform centers on four diagnostic technology lines: Handheld 1-step Molecular (instrument-free isothermal nucleic acid amplification via RPA technology invented by CTO Niall Armes), Digital Lateral Flow (connected lateral flow tests with electronic readout via exclusive Ynvisible e-paper display supply), Blood Collection & Detection (Satio Draw upper-arm patch replacing finger pricks), and traditional Lateral Flow. These are underpinned by vertically integrated capabilities including Extreme Volume Manufacturing (5 billion unit annual capacity, 16 million tests per day using 35 operators via reel-to-reel processes), Printed Electronics (integration of heaters, batteries, sensors, and antennae onto flexible materials), and In-house Molecular Reagents (peptides, oligonucleotides, recombinant proteins).

Sapphiros generates revenue through hardware sales of diagnostic products, manufacturing capacity access via strategic agreements (notably the Roche agreement providing access to 1 billion lateral flow tests annually), technology licensing, and DTC consumer wellness products via NowFuture.com and Amazon.com. Distribution occurs through multiple channels: enterprise sales to healthcare providers and government health agencies, pharmacy distribution via Cencora, exclusive distribution rights with OraSure Technologies, and DTC e-commerce. The company has accumulated over $14.6M in non-dilutive government grants from NIH RADx, ARPA-H, BARDA, and the Gates Foundation. Its customer base spans enterprise (Roche, OraSure, Cencora, Ynvisible, Visby), government (NIH, BARDA, ARPA-H, Gates Foundation), and global health (Institut Pasteur de Dakar).

Sapphiros firmographics

Firmographics
Name
Sapphiros
Legal name
Sapphiros LLC
Website
https://sapphiros.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Sapphiros is a privately held consumer diagnostics platform company developing low-cost molecular, lateral flow, and patch-based diagnostic tests. Backed by KKR and Neoenta, it serves healthcare providers, government agencies, and consumers through its 5-billion-unit annual manufacturing capacity.
Ownership category
akta.pro rank

Sapphiros industry classification

Industry
Product category
Consumer Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (6215), Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Molecular diagnostics
  • Lateral flow assays
  • Blood collection devices
  • Point-of-care testing
  • Diagnostic manufacturing

Where Sapphiros is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Sapphiros business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Products: Sale of consumer and professional diagnostic tests including lateral flow tests, molecular diagnostics, digital lateral flow devices, and blood collection/detection products. Revenue from product sales to healthcare providers, pharmacies, and consumers.
  2. Manufacturing Capacity Access: Strategic supply and manufacturing agreements providing partners like Roche access to manufacturing capacity for lateral flow tests and future molecular point-of-care tests.
  3. Technology Licensing: Licensing of proprietary technologies and platforms to partners for development and commercialization of diagnostic products.
  4. Consumer Wellness Products: Direct-to-consumer genomic and wellness testing through NowFuture brand, sold via website, Amazon.com, and retail partners.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

Sapphiros product offering

Product offering

Core offering

Sapphiros develops and manufactures low-cost, scalable consumer and clinical diagnostic platforms spanning molecular diagnostics, lateral flow, digital lateral flow, and at-home blood collection systems. The company operates a UK-based extreme volume manufacturing facility with annual capacity of 5 billion tests, combining proprietary printed electronics, in-house molecular reagents, and novel sample collection technologies. It sells through its NowFuture direct-to-consumer wellness brand and through strategic distribution partnerships with Cencora, OraSure, and Roche.

Product overview

Sapphiros is a privately held consumer diagnostics platform company offering a multi-product portfolio across four core diagnostic technology lines: Handheld 1-step Molecular (instrument-free isothermal nucleic acid testing for home and point-of-care), Digital Lateral Flow (connected lateral flow with electronic readout and NFC smartphone app connectivity), Blood Collection & Detection (Satio Draw and Satio Dot at-home blood collection patches replacing finger pricks), and Lateral Flow (extreme-scale rapid tests for global health). The company also operates a direct-to-consumer wellness sub-brand, NowFuture, offering genomic tests. Underpinning the product portfolio are four manufacturing and technology capabilities: Extreme Volume Manufacturing (EVM, producing up to 5 billion tests annually via reel-to-reel processes), Printed Electronics (reel-to-reel integration of batteries, heaters, sensors, and antennae), In-house Molecular Reagents (vertically integrated probe/protein/biochemistry production), and Visual Lateral Flow. Sapphiros also integrates Ynvisible e-paper displays into its next-generation diagnostic devices. The platform targets respiratory disease, infectious disease, and blood collection/detection focus areas.

Differentiator

Problem solved

Functional benefit

Brands

  • GoToKnow: Brand for COVID-19 antigen rapid tests and related diagnostic products
  • NowFuture
  • Biocrucible
  • Satio
  • GrapheneDx

Products and services

  • Handheld 1-step Molecular Platform Instrument-free, connected molecular diagnostics platform bringing lab-quality nucleic acid testing to point-of-care and home settings via isothermal amplification in a single user step, with built-in connectivity and multiplex capabilities for multiple answers from a single test.
  • Digital Lateral Flow Connected lateral flow testing platform with digital readout that eliminates ambiguous visual interpretation, delivering clear objective results on a large display with optional NFC-based app connectivity for tracking and healthcare system integration.
  • Blood Collection & Detection (Satio) At-home blood collection systems comprising Satio Draw (upper-arm self-collection for lab analysis) and Satio Dot (dried blood spot collection), designed to replace finger pricks and clinic visits with comfortable simple home-based sampling.
  • Lateral Flow Diagnostics (GoToKnow) Rapid lateral flow diagnostic platform engineered for extreme manufacturing scale and ultra-low costs, with five billion unit annual production capacity, integrated packaging reducing material costs and environmental impact, including the GoToKnow brand of COVID-19 antigen rapid tests.
  • NowFuture Wellness Brand Direct-to-consumer wellness brand offering genomic tests for nutrition, fitness, and sleep, with planned expansion into at-home blood collection and detection, women's health, and infectious disease testing.
  • SatioRx Intradermal Drug Delivery System Remotely controllable intradermal drug delivery device with disposable microneedle components designed for precise metered dose delivery of liquid drugs in compact, inexpensive form factor.

Quantifiable outcome

  • 5 billion tests annually manufacturing capacity
  • +4 more outcomes

Companies that use Sapphiros

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles5 records

Sapphiros technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Sapphiros partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, minor and strategic.

  • YnvisiblecoreTechnology or Integration · 11 March 2026Letter of Intent for Sapphiros to become exclusive supplier of e-paper displays for Sapphiros' lateral flow and molecular diagnostic tests. Three-year exclusive supply agreement planned. Represents Ynvisible's first commercial entry into medical diagnostics market with commercial sales expected to accelerate throughout 2026 pending FDA approval.
  • YnvisibleminorChannel Partner/ Reseller/ Distributor · 1 January 2026Delivered more than 10,000 units of e-paper displays to Sapphiros supporting clinical trials and next-generation diagnostic devices.
  • BARDAstrategicStrategic or Co-development Partner · 1 December 2025Collaboration for development of OTC single-use, low-cost digital antigen test that can detect and differentiate between respiratory viruses. The NowFuture Digital Flu/COVID Test incorporates digital readout and smartphone app connectivity.
  • RochecoreChannel Partner/ Reseller/ Distributor · 19 November 2025Strategic supply and manufacturing option agreement granting Roche exclusive rights to lateral flow technology manufacturing capacity of at least 1 billion tests annually. Includes access to Sapphiros' future instrument-free, multiplex molecular platform for point-of-care and home testing. Secures rapid global access to tests for future pandemics and health emergencies.
  • OraSure TechnologiescoreChannel Partner/ Reseller/ Distributor · 4 January 2024Strategic distribution agreement and investment. OraSure secured exclusive distribution rights for Sapphiros products in development. Partnership leverages OraSure's commercial infrastructure to scale diagnostics following regulatory approvals with initial distribution planned for 2024 and more launches expected in 2025.
  • CencoracoreChannel Partner/ Reseller/ Distributor · 22 November 2023Distribution agreement for GoToKnow COVID-19 Antigen Rapid Tests to pharmacies across the United States. Future access to Sapphiros technologies including multiplexed molecular diagnostics platform, additional rapid lateral flow tests, and Satio blood collection patches.
  • GrapheneDxcoreStrategic or Co-development Partner · 6 June 2023Strategic partnership to industrialize graphene-based biosensors for medical devices. GrapheneDx brings GFET biosensor technology, General Graphene supplies CVD graphene, and Sapphiros contributes extreme volume manufacturing and commercialization expertise.
  • General Graphene CorporationcoreTechnology or Integration · 6 June 2023Preferred supplier of sheet-based CVD graphene in roll-to-roll format for use in Sapphiros' extreme volume manufacturing facility. Annual capacity to supply 100,000 square meters of sheet graphene.
  • Institut Pasteur de DakarstrategicStrategic or Co-development Partner · 23 August 2022Strategic partnership for research, development, manufacture, and distribution of next generation healthcare technologies. Aims to enable low-cost access to vaccines and diagnostics to advance public health in Africa and beyond.
  • INTACT SolutionsstrategicStrategic or Co-development Partner · 22 August 2022Strategic partnership to jointly improve delivery of mass vaccination using SatioRx intradermal patches and INTACT aseptic fluid transfer technology. Focus on Yellow Fever, COVID (mRNA), and malaria vaccines for African Union Member States.

Scale indicators7 records

Recent moves6 records

Expansion highlights7 records

Sapphiros competitors and assessment

Company assessment

Direct peers

  • OraSure Technologies: OraSure is both a strategic investor/distribution partner and a competitor in consumer and point-of-care diagnostics (HIV self-testing, HCV, COVID). Its dual role mirrors Sapphiros' own position across consumer wellness, infectious disease, and OTC channels, making it a uniquely comparable peer.
  • Visby Medical: Visby Medical develops single-use, instrument-free PCR diagnostic platforms for respiratory infections and sexual health. It is the closest direct competitor to Sapphiros' handheld 1-step molecular platform, sharing the same instrument-free point-of-care thesis; multiple Sapphiros executives (including Teresa Abraham, KC McGrath, and Ryan Schmidt) came from Visby, making it an unusually clean comparable.
  • 23andMe: 23andMe is a consumer genomics company selling direct-to-consumer DNA tests for ancestry, health, and wellness. It is the dominant competitor to NowFuture's genomic test line for nutrition, fitness, and sleep, with comparable e-commerce and Amazon distribution.
  • Cue Health: Cue Health is a consumer-focused molecular diagnostics company offering connected at-home COVID and respiratory tests. It overlaps directly with Sapphiros' NowFuture DTC strategy and handheld molecular platform, with similar go-to-market emphasis on direct consumer and pharmacy channels.
  • iHealth Labs: iHealth Labs scaled rapidly into consumer COVID and at-home diagnostic testing through Amazon and pharmacy distribution, directly mirroring Sapphiros' NowFuture DTC and Cencora pharmacy channel strategy. Both target the same OTC rapid-test buyer.
  • Everlywell: Everlywell is a leading direct-to-consumer diagnostic testing brand offering at-home collection for a broad menu of wellness and infectious disease tests. It is the closest consumer-brand analog to Sapphiros' NowFuture genomic and wellness offering.

Emerging players

  • Tasso: Tasso develops at-home blood collection patches (OnDemand) that enable remote sample collection for laboratory analysis. It is the most direct emerging competitor to Sapphiros' Satio Draw and Satio Dot patch-based blood collection technology, sharing the same painless at-home sample collection value proposition.

Broad incumbents

  • QuidelOrtho: QuidelOrtho is a major diagnostics incumbent with QuickVue and Sofia lateral flow franchises and a broader immunoassay portfolio. It competes directly with Sapphiros in respiratory rapid antigen testing and shares the same retail pharmacy and hospital channels.
  • BD (Becton Dickinson) - Diagnostic Systems: BD's Diagnostic Systems segment includes the Veritor lateral flow platform and a broad rapid testing portfolio sold into US hospitals and pharmacies. It is an incumbent competitor with overlapping respiratory and infectious disease menu and similar scale economics ambitions.
  • Abbott Diagnostics (BinaxNOW / Panbio): Abbott is the dominant incumbent in lateral flow rapid antigen testing through BinaxNOW and Panbio, with deep retail pharmacy and global health distribution. It is the benchmark competitor for Sapphiros' lateral flow scale strategy and the legacy operator Sapphiros' founder previously ran (Alere, acquired by Abbott for $8B).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Sapphiros social profiles

Digital presence

Sapphiros compliance and trust

Trust signal

Compliance2 records

Sapphiros financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sapphiros leadership team

Management profile

Number of profiles

Profiles10 records

Sapphiros subsidiaries and ownership

Company hierarchy

Subsidiaries7 records

Sapphiros funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sapphiros M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sapphiros

What does Sapphiros do?

Sapphiros develops and manufactures low-cost, scalable consumer and clinical diagnostic platforms spanning molecular diagnostics, lateral flow, digital lateral flow, and at-home blood collection systems. The company operates a UK-based extreme volume manufacturing facility with annual capacity of 5 billion tests, combining proprietary printed electronics, in-house molecular reagents, and novel sample collection technologies. It sells through its NowFuture direct-to-consumer wellness brand and through strategic distribution partnerships with Cencora, OraSure, and Roche.

Is Sapphiros a public or private company?

Sapphiros is a private company. It is classified as private equity controlled and is currently operating.

When was Sapphiros founded?

Sapphiros was founded in 2021. It employs 11 to 50 people.

Where is Sapphiros based?

Sapphiros is headquartered in Boston, United States, in the North America region.

How does Sapphiros make money?

Four revenue lines are on record. Diagnostic Products are the primary driver. The others are manufacturing Capacity Access, technology Licensing and consumer Wellness Products.

Who are Sapphiros's main competitors?

Direct peers on record are OraSure Technologies, Visby Medical, 23andMe, Cue Health, iHealth Labs and Everlywell. Tasso is listed as an emerging player. Broad incumbents are QuidelOrtho, BD (Becton Dickinson) - Diagnostic Systems and Abbott Diagnostics (BinaxNOW / Panbio).

Does Sapphiros have an API?

No public API is recorded for Sapphiros.

What industry is Sapphiros in?

Sapphiros's product category is Consumer Diagnostics. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325413 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogSapphiros and binx health Combine to Form Onvaro, a Next-Generation Diagnostics CompanySapphiros and binx health combined to form Onvaro, a diagnostics company, with KKR, Hildred, and EQT Life Sciences investing. The company unites binx health's FDA-cleared platform with Sapphiros' technology and pipeline. Onvaro aims to expand access to decentralized testing across retail, at-home, and other channels.Stock TitanSapphiros and binx Health Combine to Form OnvaroSapphiros and binx health combined to form Onvaro, a next-generation diagnostics company. KKR, Hildred, and EQT Life Sciences are investing capital to support its growth. The company will develop a connected diagnostics layer to link test results to care.NewsfileYnvisible Advances Commercial Program with Sapphiros, Announces CFO Appointment and Adoption of Semi-Annual Financial ReportingYnvisible announced progress on its Sapphiros collaboration, with clinical trials expected to complete in Q4 2026 and a 2027 commercial launch. The company appointed Inês Paramés as CFO and adopted semi-annual financial reporting, skipping Q3 2026 interim filings. Commercialization volumes could reach high millions of units annually.YahooYnvisible Advances Commercial Program with Sapphiros, Announces CFO Appointment and Adoption of Semi-Annual Financial ReportingYnvisible announced progress on its Sapphiros collaboration, with clinical trials completing in Q4 2026 and a planned 2027 commercial launch. The company appointed Inês Paramés as CFO effective September 1, 2026, and adopted semi-annual financial reporting. Commercialization volumes could reach high millions of units annually.Stock TitanYnvisible-Sapphiros Plan 2027 Diagnostic LaunchYnvisible announced progress on its Sapphiros diagnostic collaboration, with clinical trials expected to complete in Q4 2026 and a 2027 commercial launch. The company appointed Inês Paramés as CFO and adopted semi-annual financial reporting to reduce costs and focus resources on commercialization.TradingViewYnvisible Advances Commercial Program with Sapphiros, Announces CFO Appointment and Adoption of Semi-Annual Financial ReportingYnvisible announced progress on its Sapphiros collaboration, with clinical trials expected to complete in Q4 2026 and a 2027 commercial launch. The company appointed Inês Paramés as CFO and adopted semi-annual financial reporting, effective Q3 2026, to reduce compliance costs.Pulse 2.0Sapphiros Secures $12.4 Million BARDA Award to Advance Rapid Molecular Diagnostics for Biothreat DetectionSapphiros has secured a multi-year project agreement with the Biomedical Advanced Research and Development Authority (BARDA) to advance portable, connected molecular diagnostic platforms for detecting biothreats and emerging infectious diseases. The 24-month base period focuses on developing disposable testing capabilities for blood-based pathogens using a novel closed collection system that ensures biosafety and eliminates contamination risks during sample transfer. This initiative marks Sapphiros’ second collaboration with BARDA, following a previous agreement to create a low-cost digital antigen test for respiratory viruses.BioSpaceSapphiros Secures $12.4 Million BARDA Award to Advance Rapid Molecular Diagnostics for Biothreat DetectionSapphiros received a $12.4 million multi-year BARDA award to develop rapid, portable molecular diagnostic platforms for biothreat detection. The 24-month program supports disposable testing for blood-based pathogens with a closed collection tube and phlebotomist-free sampling. This is Sapphiros' second BARDA agreement.SapphirosSapphiros Secures $12.4 Million BARDA Award to Advance Rapid Molecular Diagnostics for Biothreat DetectionSapphiros received a $12.4 million multi-year BARDA award to develop rapid molecular diagnostic platforms for biothreat detection. The program supports a 24-month base period for disposable testing in point-of-care and field settings, using a closed blood collection tube to ensure biosafety.PR NewswireSapphiros Secures $12.4 Million BARDA Award to Advance Rapid Molecular Diagnostics for Biothreat DetectionSapphiros received a $12.4 million multi-year BARDA award to develop rapid, portable molecular diagnostic platforms for biothreat detection. The program supports a 24-month base period for disposable testing of blood-based pathogens, using a closed collection tube and phlebotomist-free sampling. This is Sapphiros' second BARDA agreement.